US20130011409 Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Office

United States of America

Application Number 13509466

Application Date 12.11.2010

Publication Number 20130011409

Publication Date 10.01.2013

Grant Number 08968740

Grant Date 03.03.2015

Publication Kind B2

IPC

CPC

View more classifications

View less classifications

Applicants Shipp Margaret A.
Dana-Farber Cancer Institute, Inc.
Ouyang Jing
The Brigham and Women's Hospital, Inc.
Takeyama Kunihiko
Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)
Kutok Jeffery L.
Fundacion Sales
Rodig Scott J.
Rabinovich Gabriel
Russo Diego Omar Croci
Salatino Mariana

Inventors Shipp Margaret A.
Ouyang Jing
Takeyama Kunihiko
Kutok Jeffery L.
Rodig Scott J.
Rabinovich Gabriel
Russo Diego Omar Croci
Salatino Mariana

Agents Foley Hoag LLP

Title

(EN) Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

Abstract

(EN)

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39	Medicinal preparations containing antigens or antibodies
395	Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5	Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10	Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12	Fused cells, e.g. hybridomas
16	Animal cells
18	Murine cells, e.g. mouse cells
20	one of the fusion partners being a B lymphocyte

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18	against material from animals or humans

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18	against material from animals or humans
22	against growth factors

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39	Medicinal preparations containing antigens or antibodies

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. US20130011409 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
2317	Immunoglobulins specific features
30	characterized by aspects of specificity or valency
34	Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
2317	Immunoglobulins specific features
70	characterized by effect upon binding to a cell or to an antigen
73	Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
2317	Immunoglobulins specific features
70	characterized by effect upon binding to a cell or to an antigen
76	Antagonist effect on antigen, e.g. neutralization or inhibition of binding

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
2317	Immunoglobulins specific features
30	characterized by aspects of specificity or valency
34	Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues